Pasithea Therapeutics Corp. (KTTA)
NASDAQ: KTTA · Real-Time Price · USD
1.158
+0.018 (1.58%)
At close: Dec 30, 2025, 4:00 PM EST
1.150
-0.008 (-0.69%)
After-hours: Dec 30, 2025, 4:00 PM EST
Pasithea Therapeutics Employees
Pasithea Therapeutics had 4 employees as of December 31, 2024. The number of employees decreased by 4 or -50.00% compared to the previous year.
Employees
4
Change (1Y)
-4
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$3,373,619
Market Cap
25.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | -4 | -50.00% |
| Dec 31, 2023 | 8 | -7 | -46.67% |
| Dec 31, 2022 | 15 | 10 | 200.00% |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KTTA News
- 4 weeks ago - Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 4 weeks ago - Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data - GlobeNewsWire
- 5 weeks ago - Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients - GlobeNewsWire
- 5 weeks ago - Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study - GlobeNewsWire
- 2 months ago - Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - GlobeNewsWire
- 3 months ago - Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients - GlobeNewsWire
- 4 months ago - Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire